JNT-517
Phase 1- Indications
- Phenylketonuria
Company intelligence / Profile preview
Jnana Therapeutics
Boston, Massachusetts, United Statesjnanatx.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
Jnana’s lead asset, JNT‑517, an allosteric inhibitor of SLC6A19 for PKU, has shown effectiveness and safety in a Phase 1b/2 study. The company also has discovery programs targeting IRF3 for autoimmune/inflammatory conditions. Its RAPID chemoproteomics platform enables systematic small molecule drug discovery against previously inaccessible targets like solute carrier transporters and transcription factors.
- Therapeutic areas
- ImmunologyNeurologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Roche – multi-target collaboration/licensing deals focused on SLC transporters for immune-mediated and neurological diseases ($40M upfront + milestones exceeding $1B in first deal; second deal $50M upfront + up to $2B milestones)
Beyond the preview
Go deeper on Jnana Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jnana Therapeutics.